Skip to content
Screener

Treasury Stock at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$75.86B+0.2%
CONMED logo
CONMEDCNMD
$54.68M+294%
Treace Medical Concepts, Inc. logo
Treace Medical Concepts, Inc.TMCI
$1.42M+103%
Alphatec Holdings logo
Alphatec HoldingsATEC
$25.1M0.0%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$333.7M+113%

Other financials

Income statement

See full
Revenue$2.2B+4.8%
Gross profit$1.5B+3.8%
Operating income$326.1M+8.7%
Net income$198.3M+29.8%
EPS (diluted)$1.03+33.8%

Balance sheet

See full
Cash & equivalents$410.0M-26.4%
Total debt$7.5B-1.2%
Total equity$12.6B+0.8%
Total assets$22.8B-0.3%

Cash flow

See full
Operating cash flow$447.8M+18.4%
CapEx$54.2M+8.2%
Free cash flow$393.6M+20.0%

Valuation

See full
Market cap$18.42B-7.1%
Enterprise value$25.48B-5.0%
P/E22.8×-1.2×
P/S2.2×-0.4×

Profitability

See full
Gross margin69.9%-1.2pp
Operating margin14.2%-1.9pp
Net margin9.5%-1.0pp
FCF margin17.9%-0.9pp

Returns & leverage

See full
Return on equity6.4%-0.1pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.2×

Where this comes from

Reported directly by Zimmer Biomet Holdings in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The source filing: Zimmer Biomet Holdings’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335044
Line itemJune 30, 2026December 31, 2025
Paid-in capital10,223.210,178.6
Retained earnings11,955.111,611.0
Accumulated other comprehensive loss(163.9)(205.7)
Treasury stock, 128.8 million shares as of June 30, 2026 (123.2 million as of December 31, 2025)(9,393.7)(8,889.4)
Total Zimmer Biomet Holdings, Inc. stockholders' equity12,623.912,697.7
Noncontrolling interest8.78.1
Total Stockholders' Equity12,632.512,705.8
Total Liabilities and Stockholders' Equity$22,797.8$23,091.7

Item 1. Financial Statements

FAQ

What is Zimmer Biomet Holdings's treasury stock?
Zimmer Biomet Holdings (ZBH) reported treasury stock of $9.39B in Q2 2026.
How has Zimmer Biomet Holdings's treasury stock changed year-over-year?
Zimmer Biomet Holdings's treasury stock increased by 8.8% year-over-year, from $8.64B to $9.39B.
What is the long-term trend for Zimmer Biomet Holdings's treasury stock?
Over 5 years (2020 to 2025), Zimmer Biomet Holdings's treasury stock has grown at a 5.8% compound annual growth rate (CAGR), from $6.72B to $8.89B.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Ask your AI about Zimmer Biomet Holdings's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude